1292-P：血清血小板反应蛋白-2 水平作为一种新型肝纤维化生物标志物，随着 2 型糖尿病患者肝硬度的改善而变化,Diabetes

当前位置： X-MOL 学术 › Diabetes › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

1292-P：血清血小板反应蛋白-2 水平作为一种新型肝纤维化生物标志物，随着 2 型糖尿病患者肝硬度的改善而变化
Diabetes ( IF 6.2 ) Pub Date : 2023-06-20 , DOI: 10.2337/db23-1292-p
JIMMY H.C. MAK ₁ , HO YI CAROL FONG ₁ , YING WONG ₁ , KATHRYN C. TAN ₁ , SIU LING KAREN LAM ₁ , CHI-HO LEE ₁

Affiliation

简介：最近发现，高基线循环血小板反应蛋白-2 (TSP2) 水平与共存非酒精性脂肪肝 (NAFLD) 和 2 型糖尿病患者的肝纤维化的发生和进展相关。在这里，我们研究了循环 TSP2 水平是否随着肝纤维化的改善而变化。方法：在 DISTINCTION 研究 (NCT 03959501) 的所有参与者中测量血清 TSP2 水平，这是一项随机 1:1 开放标签干预研究，在基线时和每日 10 mg 达格列净 (N=30) 或 100 mg 西他列汀 (N =30) 24 周。使用振动控制瞬态弹性成像技术测量肝脏硬度（LS）和受控衰减参数（CAP），分别用于评估肝纤维化和脂肪变性。结果：在这 60 名基线时具有相似临床特征（平均 HbA1c 8.9%、CAP 289 dB/m 和 LS 5.9 kPa）的参与者中，尽管 HbA1c 降低程度相似，但达格列净而非西他列汀治疗导致体重 (BW) 显着改善24 周后 (p=0.012)、CAP (p=0.015) 和 LS (p=0.011)。血清 TSP2 水平从 3.07 ng/mL 显着降低至 2.90 ng/mL (p=0.012)，而西他列汀未观察到 TSP2 显着变化。Pearson相关分析显示，达格列净组血清TSP2水平变化与LS变化呈正相关（r=0.388，p=0.034），但与达格列净治疗后BW、CAP或HbA1c变化无关。结论：达格列净治疗后，血清 TSP2 水平随着 LS 的降低而降低，并且与体重、血糖控制和肝脏脂肪变性的改善无关。进一步支持血清 TSP2 水平作为 2 型糖尿病新型肝纤维化生物标志物的潜力。披露 JHC Mak：无。方宏：没有。黄耀明：没有。KC Tan：没有。林俊杰：没有。C·李：没有。

"点击查看英文标题和摘要"

1292-P: Serum Thrombospondin-2 Level as a Novel Liver Fibrosis Biomarker That Changes with Liver Stiffness Improvement in Patients with Type 2 Diabetes

Introduction: High baseline circulating thrombospondin-2 (TSP2) level was recently found to associate with both the development and progression of liver fibrosis in patients with co-existing nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver fibrosis. Methods: Serum TSP2 levels were measured in all participants of the DISTINCTION study (NCT 03959501), a randomized 1:1 open-label intervention study, at baseline and after treatment with either 10mg dapagliflozin (N=30) or 100mg sitagliptin daily (N=30) for 24 weeks. Liver stiffness (LS) and controlled attenuation parameter (CAP) were measured using vibration-controlled transient elastography for evaluation of hepatic fibrosis and steatosis, respectively. Results: Among these 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.9 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (p=0.012), CAP (p=0.015) and LS (p=0.011) after 24 weeks. Serum TSP2 level significantly decreased from 3.07 to 2.90 ng/mL (p=0.012), whereas no significant change in TSP2 was observed with sitagliptin. In Pearson correlation analysis, change in serum TSP2 levels positively correlated with change in LS in the dapagliflozin group (r=0.388, p=0.034), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment. Conclusion: Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and liver steatosis, further supporting the potential of serum TSP2 level as a novel liver fibrosis biomarker in type 2 diabetes. Disclosure J.H.C. Mak: None. H. Fong: None. Y. Wong: None. K.C. Tan: None. S. Lam: None. C. Lee: None.

更新日期：2023-06-20

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南